In Brief: Senna laxatives
This article was originally published in The Tan Sheet
Executive Summary
Senna laxatives: Nonprescription Drug Manufacturers Association receives FDA notification that a feedback letter regarding senna safety data submitted by Purdue Frederick will be issued in the near future. The agency explains that it still is reviewing human data included in the May 28, 1996 letter from the Norwalk, Conn.-based manufacturer of Senokot and Gentlax and will not schedule the feedback meeting requested by NDMA until it has issued its feedback letter ("The Tan Sheet" Nov. 18, 1996, p. 5)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning